A perioperative, single-arm multicenter Phase II academic trial to investigate the efficacy and safety of panitumumab in combination with irinotecan/5-fluorouracil/leucovorin in patients with previously untreated, wild-type KRAS, potentially resectable colorectal cancer liver metastases [Eine akademische, perioperative, einarmige, multizentrische Phase II Studie zur Überprüfung der Wirksamkeit und Sicherheit einer Kombinationstherapie mit Panitumumab und Irinotecan/5-Fluorouracil/Leucovorin in einem Patientenkollektiv mit bislang unbehandeltem, metastasierendem KRAS-Wildtyp Kolorektalkarzinom und potentiell operablen Lebermetastasen]

Trial Profile

A perioperative, single-arm multicenter Phase II academic trial to investigate the efficacy and safety of panitumumab in combination with irinotecan/5-fluorouracil/leucovorin in patients with previously untreated, wild-type KRAS, potentially resectable colorectal cancer liver metastases [Eine akademische, perioperative, einarmige, multizentrische Phase II Studie zur Überprüfung der Wirksamkeit und Sicherheit einer Kombinationstherapie mit Panitumumab und Irinotecan/5-Fluorouracil/Leucovorin in einem Patientenkollektiv mit bislang unbehandeltem, metastasierendem KRAS-Wildtyp Kolorektalkarzinom und potentiell operablen Lebermetastasen]

Recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Apr 2013

At a glance

  • Drugs Fluorouracil (Primary) ; Folinic acid (Primary) ; Irinotecan (Primary) ; Panitumumab (Primary)
  • Indications Liver metastases
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 29 Jun 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top